A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients
A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients harboring CXCR4 (X4) coreceptor-using viral variants. We developed a clinical laboratory-based genotypic tropism test for detection of CCR5-using (R5...
Saved in:
| Published in | PloS one Vol. 7; no. 9; p. e46334 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
27.09.2012
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients harboring CXCR4 (X4) coreceptor-using viral variants. We developed a clinical laboratory-based genotypic tropism test for detection of CCR5-using (R5) or X4 variants that utilizes triplicate population sequencing (TPS) followed by ultradeep sequencing (UDS) for samples classified as R5. Tropism was inferred using the bioinformatic algorithms geno2pheno([coreceptor]) and PSSM(x4r5). Virologic response as a function of tropism readout was retrospectively assessed using blinded samples from treatment-experienced subjects who received maraviroc (N = 327) in the MOTIVATE and A4001029 clinical trials. MOTIVATE patients were classified as R5 and A4001029 patients were classified as non-R5 by the original Trofile test. Virologic response was compared between the R5 and non-R5 groups determined by TPS, UDS alone, the reflex strategy and the Trofile Enhanced Sensitivity (TF-ES) test. UDS had greater sensitivity than TPS to detect minority non-R5 variants. The median log(10) viral load change at week 8 was -2.4 for R5 subjects, regardless of the method used for classification; for subjects with non-R5 virus, median changes were -1.2 for TF-ES or the Reflex Test and -1.0 for UDS. The differences between R5 and non-R5 groups were highly significant in all 3 cases (p<0.0001). At week 8, the positive predictive value was 66% for TF-ES and 65% for both the Reflex test and UDS. Negative predictive values were 59% for TF-ES, 58% for the Reflex Test and 61% for UDS. In conclusion, genotypic tropism testing using UDS alone or a reflex strategy separated maraviroc responders and non-responders as well as a sensitive phenotypic test, and both assays showed improved performance compared to TPS alone. Genotypic tropism tests may provide an alternative to phenotypic testing with similar discriminating ability. |
|---|---|
| AbstractList | A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients harboring CXCR4 (X4) coreceptor-using viral variants. We developed a clinical laboratory-based genotypic tropism test for detection of CCR5-using (R5) or X4 variants that utilizes triplicate population sequencing (TPS) followed by ultradeep sequencing (UDS) for samples classified as R5. Tropism was inferred using the bioinformatic algorithms geno2pheno[coreceptor] and PSSMx4r5. Virologic response as a function of tropism readout was retrospectively assessed using blinded samples from treatment-experienced subjects who received maraviroc (N = 327) in the MOTIVATE and A4001029 clinical trials. MOTIVATE patients were classified as R5 and A4001029 patients were classified as non-R5 by the original Trofile test. Virologic response was compared between the R5 and non-R5 groups determined by TPS, UDS alone, the reflex strategy and the Trofile Enhanced Sensitivity (TF-ES) test. UDS had greater sensitivity than TPS to detect minority non-R5 variants. The median log10 viral load change at week 8 was −2.4 for R5 subjects, regardless of the method used for classification; for subjects with non-R5 virus, median changes were −1.2 for TF-ES or the Reflex Test and −1.0 for UDS. The differences between R5 and non-R5 groups were highly significant in all 3 cases (p<0.0001). At week 8, the positive predictive value was 66% for TF-ES and 65% for both the Reflex test and UDS. Negative predictive values were 59% for TF-ES, 58% for the Reflex Test and 61% for UDS. In conclusion, genotypic tropism testing using UDS alone or a reflex strategy separated maraviroc responders and non-responders as well as a sensitive phenotypic test, and both assays showed improved performance compared to TPS alone. Genotypic tropism tests may provide an alternative to phenotypic testing with similar discriminating ability. A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients harboring CXCR4 (X4) coreceptor-using viral variants. We developed a clinical laboratory-based genotypic tropism test for detection of CCR5-using (R5) or X4 variants that utilizes triplicate population sequencing (TPS) followed by ultradeep sequencing (UDS) for samples classified as R5. Tropism was inferred using the bioinformatic algorithms geno2pheno [coreceptor] and PSSM x4r5 . Virologic response as a function of tropism readout was retrospectively assessed using blinded samples from treatment-experienced subjects who received maraviroc (N = 327) in the MOTIVATE and A4001029 clinical trials. MOTIVATE patients were classified as R5 and A4001029 patients were classified as non-R5 by the original Trofile test. Virologic response was compared between the R5 and non-R5 groups determined by TPS, UDS alone, the reflex strategy and the Trofile Enhanced Sensitivity (TF-ES) test. UDS had greater sensitivity than TPS to detect minority non-R5 variants. The median log 10 viral load change at week 8 was −2.4 for R5 subjects, regardless of the method used for classification; for subjects with non-R5 virus, median changes were −1.2 for TF-ES or the Reflex Test and −1.0 for UDS. The differences between R5 and non-R5 groups were highly significant in all 3 cases (p<0.0001). At week 8, the positive predictive value was 66% for TF-ES and 65% for both the Reflex test and UDS. Negative predictive values were 59% for TF-ES, 58% for the Reflex Test and 61% for UDS. In conclusion, genotypic tropism testing using UDS alone or a reflex strategy separated maraviroc responders and non-responders as well as a sensitive phenotypic test, and both assays showed improved performance compared to TPS alone. Genotypic tropism tests may provide an alternative to phenotypic testing with similar discriminating ability. A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients harboring CXCR4 (X4) coreceptor-using viral variants. We developed a clinical laboratory-based genotypic tropism test for detection of CCR5-using (R5) or X4 variants that utilizes triplicate population sequencing (TPS) followed by ultradeep sequencing (UDS) for samples classified as R5. Tropism was inferred using the bioinformatic algorithms geno2pheno([coreceptor]) and PSSM(x4r5). Virologic response as a function of tropism readout was retrospectively assessed using blinded samples from treatment-experienced subjects who received maraviroc (N = 327) in the MOTIVATE and A4001029 clinical trials. MOTIVATE patients were classified as R5 and A4001029 patients were classified as non-R5 by the original Trofile test. Virologic response was compared between the R5 and non-R5 groups determined by TPS, UDS alone, the reflex strategy and the Trofile Enhanced Sensitivity (TF-ES) test. UDS had greater sensitivity than TPS to detect minority non-R5 variants. The median log(10) viral load change at week 8 was -2.4 for R5 subjects, regardless of the method used for classification; for subjects with non-R5 virus, median changes were -1.2 for TF-ES or the Reflex Test and -1.0 for UDS. The differences between R5 and non-R5 groups were highly significant in all 3 cases (p<0.0001). At week 8, the positive predictive value was 66% for TF-ES and 65% for both the Reflex test and UDS. Negative predictive values were 59% for TF-ES, 58% for the Reflex Test and 61% for UDS. In conclusion, genotypic tropism testing using UDS alone or a reflex strategy separated maraviroc responders and non-responders as well as a sensitive phenotypic test, and both assays showed improved performance compared to TPS alone. Genotypic tropism tests may provide an alternative to phenotypic testing with similar discriminating ability. A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients harboring CXCR4 (X4) coreceptor-using viral variants. We developed a clinical laboratory-based genotypic tropism test for detection of CCR5-using (R5) or X4 variants that utilizes triplicate population sequencing (TPS) followed by ultradeep sequencing (UDS) for samples classified as R5. Tropism was inferred using the bioinformatic algorithms geno2pheno.sub.[coreceptor] and PSSM.sub.x4r5 . Virologic response as a function of tropism readout was retrospectively assessed using blinded samples from treatment-experienced subjects who received maraviroc (N = 327) in the MOTIVATE and A4001029 clinical trials. MOTIVATE patients were classified as R5 and A4001029 patients were classified as non-R5 by the original Trofile test. Virologic response was compared between the R5 and non-R5 groups determined by TPS, UDS alone, the reflex strategy and the Trofile Enhanced Sensitivity (TF-ES) test. UDS had greater sensitivity than TPS to detect minority non-R5 variants. The median log.sub.10 viral load change at week 8 was -2.4 for R5 subjects, regardless of the method used for classification; for subjects with non-R5 virus, median changes were -1.2 for TF-ES or the Reflex Test and -1.0 for UDS. The differences between R5 and non-R5 groups were highly significant in all 3 cases (p<0.0001). At week 8, the positive predictive value was 66% for TF-ES and 65% for both the Reflex test and UDS. Negative predictive values were 59% for TF-ES, 58% for the Reflex Test and 61% for UDS. In conclusion, genotypic tropism testing using UDS alone or a reflex strategy separated maraviroc responders and non-responders as well as a sensitive phenotypic test, and both assays showed improved performance compared to TPS alone. Genotypic tropism tests may provide an alternative to phenotypic testing with similar discriminating ability. A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients harboring CXCR4 (X4) coreceptor-using viral variants. We developed a clinical laboratory-based genotypic tropism test for detection of CCR5-using (R5) or X4 variants that utilizes triplicate population sequencing (TPS) followed by ultradeep sequencing (UDS) for samples classified as R5. Tropism was inferred using the bioinformatic algorithms geno2pheno([coreceptor]) and PSSM(x4r5). Virologic response as a function of tropism readout was retrospectively assessed using blinded samples from treatment-experienced subjects who received maraviroc (N = 327) in the MOTIVATE and A4001029 clinical trials. MOTIVATE patients were classified as R5 and A4001029 patients were classified as non-R5 by the original Trofile test. Virologic response was compared between the R5 and non-R5 groups determined by TPS, UDS alone, the reflex strategy and the Trofile Enhanced Sensitivity (TF-ES) test. UDS had greater sensitivity than TPS to detect minority non-R5 variants. The median log(10) viral load change at week 8 was -2.4 for R5 subjects, regardless of the method used for classification; for subjects with non-R5 virus, median changes were -1.2 for TF-ES or the Reflex Test and -1.0 for UDS. The differences between R5 and non-R5 groups were highly significant in all 3 cases (p<0.0001). At week 8, the positive predictive value was 66% for TF-ES and 65% for both the Reflex test and UDS. Negative predictive values were 59% for TF-ES, 58% for the Reflex Test and 61% for UDS. In conclusion, genotypic tropism testing using UDS alone or a reflex strategy separated maraviroc responders and non-responders as well as a sensitive phenotypic test, and both assays showed improved performance compared to TPS alone. Genotypic tropism tests may provide an alternative to phenotypic testing with similar discriminating ability.A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients harboring CXCR4 (X4) coreceptor-using viral variants. We developed a clinical laboratory-based genotypic tropism test for detection of CCR5-using (R5) or X4 variants that utilizes triplicate population sequencing (TPS) followed by ultradeep sequencing (UDS) for samples classified as R5. Tropism was inferred using the bioinformatic algorithms geno2pheno([coreceptor]) and PSSM(x4r5). Virologic response as a function of tropism readout was retrospectively assessed using blinded samples from treatment-experienced subjects who received maraviroc (N = 327) in the MOTIVATE and A4001029 clinical trials. MOTIVATE patients were classified as R5 and A4001029 patients were classified as non-R5 by the original Trofile test. Virologic response was compared between the R5 and non-R5 groups determined by TPS, UDS alone, the reflex strategy and the Trofile Enhanced Sensitivity (TF-ES) test. UDS had greater sensitivity than TPS to detect minority non-R5 variants. The median log(10) viral load change at week 8 was -2.4 for R5 subjects, regardless of the method used for classification; for subjects with non-R5 virus, median changes were -1.2 for TF-ES or the Reflex Test and -1.0 for UDS. The differences between R5 and non-R5 groups were highly significant in all 3 cases (p<0.0001). At week 8, the positive predictive value was 66% for TF-ES and 65% for both the Reflex test and UDS. Negative predictive values were 59% for TF-ES, 58% for the Reflex Test and 61% for UDS. In conclusion, genotypic tropism testing using UDS alone or a reflex strategy separated maraviroc responders and non-responders as well as a sensitive phenotypic test, and both assays showed improved performance compared to TPS alone. Genotypic tropism tests may provide an alternative to phenotypic testing with similar discriminating ability. A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients harboring CXCR4 (X4) coreceptor-using viral variants. We developed a clinical laboratory-based genotypic tropism test for detection of CCR5-using (R5) or X4 variants that utilizes triplicate population sequencing (TPS) followed by ultradeep sequencing (UDS) for samples classified as R5. Tropism was inferred using the bioinformatic algorithms geno2pheno [coreceptor] and PSSM x4r5 . Virologic response as a function of tropism readout was retrospectively assessed using blinded samples from treatment-experienced subjects who received maraviroc (N = 327) in the MOTIVATE and A4001029 clinical trials. MOTIVATE patients were classified as R5 and A4001029 patients were classified as non-R5 by the original Trofile test. Virologic response was compared between the R5 and non-R5 groups determined by TPS, UDS alone, the reflex strategy and the Trofile Enhanced Sensitivity (TF-ES) test. UDS had greater sensitivity than TPS to detect minority non-R5 variants. The median log 10 viral load change at week 8 was −2.4 for R5 subjects, regardless of the method used for classification; for subjects with non-R5 virus, median changes were −1.2 for TF-ES or the Reflex Test and −1.0 for UDS. The differences between R5 and non-R5 groups were highly significant in all 3 cases (p<0.0001). At week 8, the positive predictive value was 66% for TF-ES and 65% for both the Reflex test and UDS. Negative predictive values were 59% for TF-ES, 58% for the Reflex Test and 61% for UDS. In conclusion, genotypic tropism testing using UDS alone or a reflex strategy separated maraviroc responders and non-responders as well as a sensitive phenotypic test, and both assays showed improved performance compared to TPS alone. Genotypic tropism tests may provide an alternative to phenotypic testing with similar discriminating ability. |
| Audience | Academic |
| Author | Johnson, Erik P. Platt, Jamie L. Biswas, Pinaki Chapman, Douglass S. Su, Zhaohui Pesano, Rick L. Kagan, Ron M. Siaw, Martin |
| AuthorAffiliation | National Institute of Allergy and Infectious Diseases, United States of America 1 Department of Infectious Diseases, Quest Diagnostics Nichols Institute, San Juan Capistrano, California, United States of America 4 Outcome Sciences, Cambridge, Massachusetts, United States of America 2 Pfizer, Collegeville, Pennsylvania, United States of America 3 Pfizer, New York, New York, United States of America |
| AuthorAffiliation_xml | – name: 3 Pfizer, New York, New York, United States of America – name: 4 Outcome Sciences, Cambridge, Massachusetts, United States of America – name: 1 Department of Infectious Diseases, Quest Diagnostics Nichols Institute, San Juan Capistrano, California, United States of America – name: National Institute of Allergy and Infectious Diseases, United States of America – name: 2 Pfizer, Collegeville, Pennsylvania, United States of America |
| Author_xml | – sequence: 1 givenname: Ron M. surname: Kagan fullname: Kagan, Ron M. – sequence: 2 givenname: Erik P. surname: Johnson fullname: Johnson, Erik P. – sequence: 3 givenname: Martin surname: Siaw fullname: Siaw, Martin – sequence: 4 givenname: Pinaki surname: Biswas fullname: Biswas, Pinaki – sequence: 5 givenname: Douglass S. surname: Chapman fullname: Chapman, Douglass S. – sequence: 6 givenname: Zhaohui surname: Su fullname: Su, Zhaohui – sequence: 7 givenname: Jamie L. surname: Platt fullname: Platt, Jamie L. – sequence: 8 givenname: Rick L. surname: Pesano fullname: Pesano, Rick L. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23029482$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk91q3DAQhU1JaX7aNyitoVDai93KkleWelEIIU0WAgn5uxVaeexVsCVH0rbJi_R5O9tsym4IpfjCYvSdI81htJttOe8gy94WZFywqvhy4xfB6W48YHlMSMkZK19kO4VkdMQpYVtr6-1sN8YbQiZMcP4q26aMUFkKupP92s-PwPl0P1iTX0JMeeNDfjy9HhX5ZfCDjX1-4PuZdda1-YV2LYT8Am4X4Myy8tOmeX7VpaBrgGF95yxAbU2K-bUNvvMt-p9DxNtGyK1Dc9CpB5dGh3cDBIsqqPMznXCV4uvsZaO7CG9W_73s6vvh5cHx6OT0aHqwfzIyXNI0qqtZ1RBZc1HMakEngnEtS0YLUUpoJlVlZCEkmelSsxmwhnEwwKTkrKG01oTtZe8ffIfOR7WKNKqCUT6ZsIJTJKYPRO31jRqC7XW4V15b9afgQ6t0SNZ0oGRNCNSmMaKmpW6EBlERWWgKouHaVOj1bXXaYtYjiZ0G3W2Ybu44O1et_6FYOZGSSDT4tDIIHoOOSfU2Gug67cAv8N5E0JJwKpfohyfo892tqFZjA9Y1Hs81S1O1X0o0K6tKIDV-hsKvht4anL_GYn1D8HlDgEyCu9TqRYxqenH-_-zp9Sb7cY2dg-7SPPpukSyO1Sb4bj3pvxE_Dj4CXx8AE3yMARplbNJLH2zNdpikWr6yx9DU8pWp1StDcflE_Oj_T9lv9a0tZQ |
| CitedBy_id | crossref_primary_10_1111_pme_12417 crossref_primary_10_1089_aid_2013_0123 crossref_primary_10_1146_annurev_genom_091212_153406 crossref_primary_10_1007_s11908_014_0401_5 crossref_primary_10_1186_1742_6405_11_14 crossref_primary_10_7883_yoken_JJID_2017_482 crossref_primary_10_1371_journal_pone_0127816 crossref_primary_10_2174_1570162X16666180515124836 crossref_primary_10_1016_j_jcv_2014_06_013 crossref_primary_10_3109_1040841X_2013_867829 crossref_primary_10_2217_fvl_2016_0080 crossref_primary_10_1038_srep42215 crossref_primary_10_1186_s40249_017_0377_0 crossref_primary_10_1128_AAC_00038_16 crossref_primary_10_1371_journal_pone_0102857 crossref_primary_10_1089_aid_2012_0284 crossref_primary_10_1177_1087057113505906 crossref_primary_10_1038_srep16944 crossref_primary_10_1128_JCM_00510_13 crossref_primary_10_1097_QAD_0000000000000269 crossref_primary_10_1128_AAC_02710_13 crossref_primary_10_2217_fvl_13_21 crossref_primary_10_1093_infdis_jit656 crossref_primary_10_1097_QAD_0000000000000267 crossref_primary_10_1186_s12981_018_0206_y crossref_primary_10_1016_j_dib_2015_12_008 crossref_primary_10_1016_j_jmoldx_2015_07_004 crossref_primary_10_1128_JVI_02778_12 crossref_primary_10_1089_aid_2013_0155 crossref_primary_10_1111_nyas_12777 crossref_primary_10_1016_j_jcv_2018_02_008 crossref_primary_10_1186_s12981_015_0055_x crossref_primary_10_1128_AAC_01534_13 crossref_primary_10_1128_JCM_00739_12 crossref_primary_10_1002_jmv_23853 crossref_primary_10_1016_j_antiviral_2013_03_017 crossref_primary_10_1093_jac_dkt426 crossref_primary_10_1093_infdis_jiab413 crossref_primary_10_1093_cid_cit125 crossref_primary_10_1093_infdis_jix430 crossref_primary_10_1016_j_hjb_2016_12_007 crossref_primary_10_1007_s10096_018_3235_5 crossref_primary_10_1128_JVI_00193_20 crossref_primary_10_1038_srep08543 crossref_primary_10_3390_v16040510 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2012 Public Library of Science Kagan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2012 Kagan et al 2012 Kagan et al |
| Copyright_xml | – notice: COPYRIGHT 2012 Public Library of Science – notice: Kagan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2012 Kagan et al 2012 Kagan et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0046334 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest SciTech Premium Collection Technology Collection Materials Science & Engineering Database ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest SciTech Premium Collection Technology Collection Advanced Technologies & Aerospace Collection ProQuest SciTech Premium Collection Natural Science Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine Biology |
| DocumentTitleAlternate | Genotypic Testing for HIV-1 Tropism |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1326553162 oai_doaj_org_article_9d00edcfc8d24af8ae87091a2e8f6ac7 PMC3459909 2943690781 A498244778 23029482 10_1371_journal_pone_0046334 |
| Genre | Clinical Trial Journal Article |
| GeographicLocations | United States New York California United States--US San Juan Capistrano California |
| GeographicLocations_xml | – name: United States – name: New York – name: San Juan Capistrano California – name: California – name: United States--US |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPNFZ IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RIG RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM BBORY CGR CUY CVF ECM EIF NPM PV9 RZL PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c692t-d7b7f09d681bd825836a94321849ef577c91890ba4a3be3f36ece39963f22da03 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:14:23 EST 2021 Wed Aug 27 01:26:55 EDT 2025 Thu Aug 21 18:11:25 EDT 2025 Tue Aug 05 10:31:03 EDT 2025 Fri Jul 25 10:26:34 EDT 2025 Tue Jun 17 20:38:50 EDT 2025 Tue Jun 10 20:43:16 EDT 2025 Fri Jun 27 05:08:03 EDT 2025 Fri Jun 27 04:33:11 EDT 2025 Thu May 22 21:22:17 EDT 2025 Fri May 16 01:56:55 EDT 2025 Thu Apr 24 23:08:01 EDT 2025 Tue Jul 01 02:44:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-d7b7f09d681bd825836a94321849ef577c91890ba4a3be3f36ece39963f22da03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 Competing Interests: The authors have read the journal's policy and have the following conflicts: Authors RMK, EPJ, MS, JLP and RLP are employed by Quest Diagnostics, a diagnostic testing company that offers diagnostic tests for HIV. Authors PB and DSC are employed by a pharmaceutical company, Pfizer Inc, that sells antiretroviral drugs. ZS was employed as a biostatistics consultant for this project. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. Conceived and designed the experiments: RMK ZS DSC RLP. Performed the experiments: EPJ MS. Analyzed the data: RMK PB DSC ZS. Contributed reagents/materials/analysis tools: RMK JLP RLP. Wrote the paper: RMK. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0046334 |
| PMID | 23029482 |
| PQID | 1326553162 |
| PQPubID | 1436336 |
| PageCount | e46334 |
| ParticipantIDs | plos_journals_1326553162 doaj_primary_oai_doaj_org_article_9d00edcfc8d24af8ae87091a2e8f6ac7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3459909 proquest_miscellaneous_1082406299 proquest_journals_1326553162 gale_infotracmisc_A498244778 gale_infotracacademiconefile_A498244778 gale_incontextgauss_ISR_A498244778 gale_incontextgauss_IOV_A498244778 gale_healthsolutions_A498244778 pubmed_primary_23029482 crossref_citationtrail_10_1371_journal_pone_0046334 crossref_primary_10_1371_journal_pone_0046334 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-09-27 |
| PublicationDateYYYYMMDD | 2012-09-27 |
| PublicationDate_xml | – month: 09 year: 2012 text: 2012-09-27 day: 27 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2012 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | 10559367 - J Virol. 1999 Dec;73(12):10489-502 9440686 - Nature. 1998 Jan 15;391(6664):240 17659080 - Genome Biol. 2007;8(7):R143 19996764 - J Acquir Immune Defic Syndr. 2010 Feb;53(2):167-75 9499115 - J Virol. 1998 Mar;72(3):2509-15 17600086 - Genome Res. 2007 Aug;17(8):1195-201 19439544 - J Clin Microbiol. 2009 Jul;47(7):2292-4 21429803 - Lancet Infect Dis. 2011 May;11(5):394-407 14671134 - J Virol. 2004 Jan;78(1):524-30 21099667 - AIDS. 2011 Jan 14;25(2):257-64 20512044 - J Acquir Immune Defic Syndr. 2010 Aug;54(5):506-10 22135472 - Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20166-71 17634242 - J Virol. 2007 Oct;81(19):10209-19 18018768 - Antivir Ther. 2007;12(7):1097-106 21592414 - BMC Genomics. 2011;12:245 17683002 - Clin Infect Dis. 2007 Sep 1;45(5):643-9 22286879 - Intervirology. 2012;55(2):113-7 21734029 - J Clin Microbiol. 2011 Sep;49(9):3380-2 19424056 - AIDS. 2009 Jun 19;23(10):1209-18 16923919 - J Leukoc Biol. 2006 Nov;80(5):965-72 14645592 - J Virol. 2003 Dec;77(24):13376-88 21890778 - Clin Infect Dis. 2011 Oct;53(7):732-42 17596837 - J Med Virol. 2007 Aug;79(8):1040-6 21248683 - J Vis Exp. 2010;(46). pii: 2531. doi: 10.3791/2531 20530226 - Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40 20151839 - J Infect Dis. 2010 Mar 15;201(6):803-13 19874596 - BMC Bioinformatics. 2009;10:362 19440459 - Open Virol J. 2008;2:8-14 17116663 - Antimicrob Agents Chemother. 2007 Feb;51(2):566-75 20427374 - J Antimicrob Chemother. 2010 Jul;65(7):1486-92 20736814 - AIDS. 2010 Oct 23;24(16):2517-25 21288824 - J Infect Dis. 2011 Jan 15;203(2):237-45 16570858 - Curr Top Microbiol Immunol. 2006;303:97-120 18614865 - AIDS. 2008 Jul 31;22(12):1425-31 20591141 - Retrovirology. 2010;7:56 16056220 - Nature. 2005 Sep 15;437(7057):376-80 18832245 - N Engl J Med. 2008 Oct 2;359(14):1442-55 16251317 - Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32 19479085 - PLoS One. 2009;4(5):e5683 21427401 - Clin Infect Dis. 2011 Apr 1;52(7):925-8 12876899 - AIDS Rev. 2003 Apr-Jun;5(2):104-12 9034141 - J Exp Med. 1997 Feb 17;185(4):621-8 19874179 - J Infect Dis. 2009 Dec 1;200(11):1724-8 18301059 - AIDS. 2008 Feb 19;22(4):469-79 21752271 - Retrovirology. 2011;8:56 16641282 - J Virol. 2006 May;80(10):4909-20 19432546 - J Infect Dis. 2009 Jun 1;199(11):1638-47 18832244 - N Engl J Med. 2008 Oct 2;359(14):1429-41 19261623 - J Antimicrob Chemother. 2009 May;63(5):1006-10 1905842 - Science. 1991 Jul 5;253(5015):71-4 |
| References_xml | – reference: 21890778 - Clin Infect Dis. 2011 Oct;53(7):732-42 – reference: 21427401 - Clin Infect Dis. 2011 Apr 1;52(7):925-8 – reference: 17600086 - Genome Res. 2007 Aug;17(8):1195-201 – reference: 19874596 - BMC Bioinformatics. 2009;10:362 – reference: 17634242 - J Virol. 2007 Oct;81(19):10209-19 – reference: 21592414 - BMC Genomics. 2011;12:245 – reference: 18018768 - Antivir Ther. 2007;12(7):1097-106 – reference: 19996764 - J Acquir Immune Defic Syndr. 2010 Feb;53(2):167-75 – reference: 19479085 - PLoS One. 2009;4(5):e5683 – reference: 19874179 - J Infect Dis. 2009 Dec 1;200(11):1724-8 – reference: 1905842 - Science. 1991 Jul 5;253(5015):71-4 – reference: 14671134 - J Virol. 2004 Jan;78(1):524-30 – reference: 22135472 - Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20166-71 – reference: 20736814 - AIDS. 2010 Oct 23;24(16):2517-25 – reference: 19440459 - Open Virol J. 2008;2:8-14 – reference: 21752271 - Retrovirology. 2011;8:56 – reference: 19424056 - AIDS. 2009 Jun 19;23(10):1209-18 – reference: 19432546 - J Infect Dis. 2009 Jun 1;199(11):1638-47 – reference: 16251317 - Antimicrob Agents Chemother. 2005 Nov;49(11):4721-32 – reference: 18301059 - AIDS. 2008 Feb 19;22(4):469-79 – reference: 16641282 - J Virol. 2006 May;80(10):4909-20 – reference: 21248683 - J Vis Exp. 2010;(46). pii: 2531. doi: 10.3791/2531 – reference: 20512044 - J Acquir Immune Defic Syndr. 2010 Aug;54(5):506-10 – reference: 16923919 - J Leukoc Biol. 2006 Nov;80(5):965-72 – reference: 22286879 - Intervirology. 2012;55(2):113-7 – reference: 20427374 - J Antimicrob Chemother. 2010 Jul;65(7):1486-92 – reference: 18614865 - AIDS. 2008 Jul 31;22(12):1425-31 – reference: 16056220 - Nature. 2005 Sep 15;437(7057):376-80 – reference: 10559367 - J Virol. 1999 Dec;73(12):10489-502 – reference: 20530226 - Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40 – reference: 18832244 - N Engl J Med. 2008 Oct 2;359(14):1429-41 – reference: 9499115 - J Virol. 1998 Mar;72(3):2509-15 – reference: 19439544 - J Clin Microbiol. 2009 Jul;47(7):2292-4 – reference: 20591141 - Retrovirology. 2010;7:56 – reference: 21429803 - Lancet Infect Dis. 2011 May;11(5):394-407 – reference: 17596837 - J Med Virol. 2007 Aug;79(8):1040-6 – reference: 17659080 - Genome Biol. 2007;8(7):R143 – reference: 9034141 - J Exp Med. 1997 Feb 17;185(4):621-8 – reference: 16570858 - Curr Top Microbiol Immunol. 2006;303:97-120 – reference: 21734029 - J Clin Microbiol. 2011 Sep;49(9):3380-2 – reference: 9440686 - Nature. 1998 Jan 15;391(6664):240 – reference: 20151839 - J Infect Dis. 2010 Mar 15;201(6):803-13 – reference: 14645592 - J Virol. 2003 Dec;77(24):13376-88 – reference: 17116663 - Antimicrob Agents Chemother. 2007 Feb;51(2):566-75 – reference: 19261623 - J Antimicrob Chemother. 2009 May;63(5):1006-10 – reference: 21099667 - AIDS. 2011 Jan 14;25(2):257-64 – reference: 21288824 - J Infect Dis. 2011 Jan 15;203(2):237-45 – reference: 12876899 - AIDS Rev. 2003 Apr-Jun;5(2):104-12 – reference: 17683002 - Clin Infect Dis. 2007 Sep 1;45(5):643-9 – reference: 18832245 - N Engl J Med. 2008 Oct 2;359(14):1442-55 |
| SSID | ssj0053866 |
| Score | 2.291587 |
| Snippet | A tropism test is required prior to initiation of CCR5 antagonist therapy in HIV-1 infected individuals, as these agents are not effective in patients... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e46334 |
| SubjectTerms | Acquired immune deficiency syndrome Adult Aged AIDS Algorithms Anti-HIV Agents - metabolism Anti-HIV Agents - pharmacology Antiretroviral drugs Biological Assay Biology Biomarkers, Pharmacological CCR5 protein CCR5 Receptor Antagonists Clinical trials CXCR4 protein Cyclohexanes - metabolism Cyclohexanes - pharmacology Diagnosis Female Genetic aspects Genotyping Techniques Glycoproteins High-Throughput Nucleotide Sequencing HIV HIV infections HIV Infections - drug therapy HIV Infections - metabolism HIV Infections - virology HIV tests HIV-1 - drug effects HIV-1 - physiology Human immunodeficiency virus Humans Infectious diseases Male Medical research Medicine Middle Aged Patients Predictive Value of Tests Receptors, CCR5 - metabolism Receptors, CXCR4 - metabolism Retrospective Studies Sensitivity Sensitivity enhancement Triazoles - metabolism Triazoles - pharmacology Tropism Viral Tropism Viruses |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZQT1wQy2sLCxiEBByy29iJHR8LYtVFAiSWXe0t8hMqlTRq0gN_hN_LTOJGDVppOXBsPK6SmfH4m2TmMyGvRIqbYJYmJrV5AlGSJyYPeeJ4kEoyDz6F_c6fPovFRfbxKr_aO-oLa8J6euBecSfKzWbe2WALxzIdCu3Bw1SqmS-C0LbrI4ffu2Sqj8GwioWIjXJcpifRLsf1uvLHmBJyno02oo6vf4jKk3q1bq6DnH9XTu5tRad3yZ2IIem8v_cDcstX98hBXKUNfROppN_eJ7_nFElY21_10lIAlS0FjEoXZ5dJStvNul42Pym4nOlOiaDnXQ8wjdXVeAXf0tLtCm7CeV_vj9Qb_MLTNhT75Lr4STd9ua2ny4oO9euJH7iUHY0krs0DcnH64dv7RRJPYkisUKxNnDQyzJQTAHId5JQFF1plHNND5UMupVVg85nRmebG88CFtx6gj-CBMadn_CGZVKD7Q0KDypQ0EEkMg-SkyLV0MDUzQguvglFTwndmKW2kKcfTMlZl9-1NQrrSa7lEY5bRmFOSDLPqnqbjBvl3aPFBFkm2uwvgemV0vfIm15uS5-gvZd-xOoSKcg7PBahJymJKXnYSSLRRYSXPd71tmvLsy-U_CJ1_HQm9jkJhDeqwOnZPwDMhgddI8mgkCeHCjoYP0bt3WmlAR0zkEIkFg5k7j79--MUwjH-K1XmVX28bJJlFYAjIZkoe9Qtk0CykuExlBcyWo6UzUv14pFr-6HjOeZYDVlKP_4etnpDbAHUZVvoweUQm7WbrnwKcbM2zLnL8ATJXeCo priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELegvPCCGF8rDDAICXjI1tiJHT-hgpg6JGBaP7S3yE7sUakkoWkf-Ef4e7lL3GxBE_DY-Jwmd77L7-zzz4S8EiF-BKMwMGEWBxAleWBiFwc5d1JJZmFM4X7nz1_EZB59Oo_P_YRb7csqdzGxCdR5meEc-RFkTSKGASPYu-pHgKdG4eqqP0LjJrmF1GVY0iXPu4QLfFkIv12Oy_DIW-ewKgt7iIkh51Hvc9Sw9nexeVCtyvo64Pln_eSVD9LxXXLHI0k6bk2_R27Y4h7Z875a0zeeUPrtffJrTOFHuflZLTM6g_-ggFTp5GQRhHS2Lqtl_Z1CXDDNWRF02uwEptO2xhqv4Fwtna_gIXJrq6stp2tc59nUdLFct1GUnrVFt5YuC7i5r2IPLhmVc3raUrnWD8j8-OPswyTw5zEEmVBsE-TSSDdSuQCom0NmmXChVcQxSVTWxVJmCiw_MjrS3FjuuLCZBQAkuGMs1yP-kAwK0P0-oU5FShqIJ4ZBipLEWubQNTJCC6ucUUPCd2ZJM09WjmdmrNJmBU5C0tJqOUVjpt6YQxJ0vaqWrOMf8u_R4p0sUm03F8r1Reo9N1X5aASmdlmSs0i7RFsIcSrUzCZO6EwOyXMcL2m7b7ULGOkY3guwk5TJkLxsJJBuo8B6ngu9rev05OviP4SmZz2h117IlaCOTPs9FPBOSOPVkzzoSULQyHrN-zi6d1qp00v3gp67EX9984uuGW-KNXqFLbc1Us0iPAR8MySPWgfpNAuJLlNRAr1lz3V6qu-3FMtvDds5j2JATOrx3x_rCbkNUJZhJQ-TB2SwWW_tU4CLG_OsiQm_AYPrbFc priority: 102 providerName: ProQuest |
| Title | A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23029482 https://www.proquest.com/docview/1326553162 https://www.proquest.com/docview/1082406299 https://pubmed.ncbi.nlm.nih.gov/PMC3459909 https://doaj.org/article/9d00edcfc8d24af8ae87091a2e8f6ac7 http://dx.doi.org/10.1371/journal.pone.0046334 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELe27oUXxPhaYRSDkICHTImd2PEDQt200iFtVP1S36J8OFulkoSkldg_wt_LXZKGBRUBL5Ean53mznf-XXy-I-SNsHARtC0jsELHACvJjcCJHSPisVSSaZhTeN758koMZ_bnhbPYI9uarTUDi52uHdaTmuWrk-_fbj-Cwn8oqzZIa9vpJEsTfYIOH-f2PjmAtUmiql7azb4CaHe5e4moxRDM5PVhuj-N0lqsypz-jeXuZKu02AVLf4-uvLNcDR6Q-zXOpP1qYhySPZ08JIe1Jhf0XZ1u-v0j8qNP4Ue6vs2WIZ3CMyjgWDq8mBsWneZptiy-UrAaQVlJgk7Kc8J0UkVg4x38kktnK_gTkdbZ3ZZRjrtA64LOl3llY-m4CsnVdJnA4HWMu_Er33JER1Wi1-IxmQ3Op2dDo67WYIRCsbURyUDGpooEAOEI_E6XC1_ZHF1IpWNHylDBvDAD3_Z5oHnMhQ41wCPBY8Yi3-RPSCcB3h8RGitbyQCsTcDAgXEdX0bQ1Q6EL7SKA9UlfCsWL6xTmWNFjZVX7s9JcGkqLnsoTK8WZpcYTa-sSuXxF_pTlHhDi4m4yxtpfu3Veu2pyDRB1HHoRsz2Y9fXYACV5TPtxsIPZZe8xPniVadaG3Pi9eG9AFlJ6XbJ65ICk3EkGO1z7W-Kwrv4Mv8Hosm4RfS2JopTYEfo1ycs4J0wyVeL8rhFCSYlbDUf4ezecqUAHjHhgLUWDHpuZ_zu5ldNMw6KEXyJTjcFJqJF8Ajop0ueVgrScBbcYKZsF3rLluq0WN9uSZY3ZS50bjuAp9Sz_5Ttc3IPkC_DwB8mj0lnnW_0C0CX66BH9uVCwtU9s_A6-NQjB6fnV6Nxr_xe0ysNyk8iCX9s |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lc9MwENaUcIALQ3k1UKhgYICDW1uyJevAMOHRSeiDTptkcjN-yCUzwTZxMkz_CD-D38iurbg10wEuPcZaKbJ29e2utdol5LlwUAm6jhU5sWcBSnIr8lLPSngqlWQaZArvOx8civ7I_TTxJmvk1-ouDIZVrjCxAuokj_Eb-Q54TcIDgRHsbfHdwqpReLq6KqFRi8WePvsBLlv5ZvAB-PuCsd2Pw_d9y1QVsGKh2MJKZCRTWyUCDLYE_COfi1C5HF0dpVNPyljB_O0odEMeaZ5yoWMNalzwlLEktDmMe41cB8Vr446Sk8bBA-wQwlzP49LZMdKwXeSZ3kZHlHO3pf6qKgGNLugUs7y8zND9M17zggLcvU1uGcuV9mpRWydrOrtD1g02lPSVSWD9-i752aPwI1-cFdOYDuE_KFjGtD8YWw4dzvNiWn6jgENRVZuCnlQ3j-lJHdONT_DbMB3NYBKJ1sXFlqM5nistSjqezmvUpsd1kK-m0wwGN1Hz1nkG54Qe1aljy3tkdCWcuk86Gaz9BqGpcpWMAL8iBi6R74Uyga5uJEKhVRqpLuErtgSxSY6ONTpmQXXiJ8FJqlc5QGYGhpldYjW9ijo5yD_o3yHHG1pM7V09yOengUGKQCW2DaxOYz9hbpj6oQZIVU7ItJ-KMJZdsoXyEtT3ZBuACnrwXmCrSel3ybOKAtN7ZBg_dBouyzIYfB7_B9HJcYvopSFKc1iOODR3NuCdMG1Yi3KzRQkgFbeaN1C6V6tSBufbGXquJP7y5qdNMw6KMYGZzpclprZFcxTsqS55UG-QZmXBsWbK9aG3bG2d1tK3W7Lp1yq7Onc9sNDUw79Pa4vc6A8P9oP9weHeI3ITzGiGUURMbpLOYr7Uj8FUXURPKnyg5MtVA9JvqlWodA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGkRAviPFvhcEMAgEP2Ro7seMHhAajahmMaWurvWX5Y49KJQlNJ7Qvwofh03GXuNmCJuBlj43Pbnx3_vkuvjsT8ly4uAl6rhO7ie8ASnIn9o3vpNxIJZkGncJ85897YjD2Ph75Ryvk1zIXBsMql5hYAXWaJ_iNfAu8JuGDwgi2ZWxYxP5O_23x3cEbpPCkdXmdRq0iu_rsB7hv5ZvhDsj6BWP9D6P3A8feMOAkQrGFk8pYmp5KBRhvKfhKAReR8ji6PUobX8pEwVx6ceRFPNbccKETDVu64IaxNOpxGPcauS657-Iak0eNswc4IoRN1ePS3bKasVnkmd5Ep5Rzr7UVVjcGNPtCp5jl5WVG75-xmxc2w_5tcstasXS7VrtVsqKzO2TV4kRJX9li1q_vkp_bFH7ki7NimtAR_AcFK5kOhhPHpaN5XkzLbxQwKa7uqaCHVRYyPazju_EJfiem4xm8RKp1cbFlf45nTIuSTqbzGsHpQR3wq-k0g8FtBL1zXs05pft1GdnyHhlfiaTuk04GvF8j1ChPyRiwLGbgHgV-JFPo6sUiElqZWHUJX4olTGyhdLyvYxZWp38SHKaayyEKM7TC7BKn6VXUhUL-Qf8OJd7QYpnv6kE-PwktaoQq7fVA1CYJUuZFJog0wKtyI6YDI6JEdskG6ktY58w2YBVuw7zAbpMy6JJnFQWW-shw0ZxEp2UZDr9M_oPo8KBF9NISmRzYkUQ2fwPmhCXEWpTrLUoArKTVvIbaveRKGZ4vbei51PjLm582zTgoxgdmOj8tscwtmqZgW3XJg3qBNJwFJ5spL4DesrV0Wqxvt2TTr1Wlde75YK2ph39_rQ1yA6Ao_DTc231EboJFzTCgiMl10lnMT_VjsFoX8ZMKHig5vmo8-g2Gnqyq |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Genotypic+Test+for+HIV-1+Tropism+Combining+Sanger+Sequencing+with+Ultradeep+Sequencing+Predicts+Virologic+Response+in+Treatment-Experienced+Patients&rft.jtitle=PloS+one&rft.au=Kagan%2C+Ron+M.&rft.au=Johnson%2C+Erik+P.&rft.au=Siaw%2C+Martin&rft.au=Biswas%2C+Pinaki&rft.date=2012-09-27&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=7&rft.issue=9&rft.spage=e46334&rft_id=info:doi/10.1371%2Fjournal.pone.0046334&rft.externalDBID=n%2Fa&rft.externalDocID=10_1371_journal_pone_0046334 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |